Abstract: Background. Cutaneous squamous cell carcinoma (CSCC) is the second most common nonmelanoma skin cancer. Most of the approximately 250,000 cases occurring annually in the United States are small, nonaggressive, and cured by excision alone. However, a subset of these tumors which are defined by poorly differentiated histology, large tumor size, invasion of adjacent structures, and/or regional metastases can prove resistant to treatment despite adjuvant radiotherapy and can have an increased risk of recurrence and nodal metastasis. Novel therapeutic approaches are necessary to improve the outcomes for patients with aggressive CSCC.
Cutaneous squamous cell carcinoma (CSCC) is the second most common type of nonmelanoma skin cancer. The annual incidence is estimated at 1 case per 1000 individuals, and approximately 250,000 cases of CSCC occurred in the year 2001 alone. 1 The causespecific mortality rate due to CSCC is less than 1% overall, but rises to 30% at 3 years for those patients whose tumors have aggressive features.
2 CSCC incidence has risen dramatically over the past 2 decades because of lifestyle changes leading to increased voluntary exposure to sunlight. 3 The standard of care for the management of CSCC is surgical excision. However, even adequate initial treatment of poorly differentiated CSCC can be complicated by a recurrence rate of up to 25%. Recent successes involving the therapeutic use of antibodies and small molecule inhibitors against tyrosine kinases have generated considerable interest in research aimed at targeting these receptors in a wide variety of malignancies. In an attempt to improve the treatment of CSCC, we explored the effect of inhibition of 2 of these receptors on cutaneous tumor growth in vitro and in vivo.
The insulin-like growth factor-I receptor (IGF-IR) is a ubiquitous transmembrane tyrosine kinase composed of 2 extracellular alpha subunits and 2 intracellular beta subunits. [4] [5] [6] Ligand binding (IGF1 or IGF2) to the extracellular alpha subunits trigger conformational changes in the beta subunits activating the receptors tyrosine kinase activity, which in turn activates downstream signaling cascades, including the phosphatidylinositol 3-kinase/AKT and Ras/Raf/mitogen-activated protein kinase (MAPK) pathways. [6] [7] [8] [9] [10] [11] Numerous human tumors have been shown to overexpress IGF-IR or have increased IGF-IR kinase activity resulting in enhanced proliferation, protection from apoptosis, stimulation of migration and invasion, and stimulation of angiogenesis. Targeted therapies, including insulin-like growth factor (IGF) binding proteins, human monoclonal antibodies, and small-molecule tyrosine kinase inhibitors against IGF-IR, have been developed and show promise for therapeutic use in both in vitro and in vivo experiments. [12] [13] [14] [15] [16] A12, a high-affinity human monoclonal antibody to IGF-IR, has been shown to induce apoptosis and inhibit tumor growth by competitively binding to the receptor and inducing IGF-IR internalization and downregulation. Experimentally, A12 has been shown to inhibit the growth of breast, pancreatic, colon, and renal tumors, both in vitro and in vivo with little toxicity or weight loss in nude mouse models. 13 The epidermal growth factor receptor (EGFR), a member of the ErbB tyrosine kinase receptor family, is a transmembrane glycoprotein receptor. Activation of EGFR stimulates phosphorylation of downstream signaling cascades that ultimately regulate cell proliferation, migration, adhesion, differentiation, and survival. [17] [18] [19] EGFR is frequently overexpressed in mucosal squamous cell carcinoma (SCC) and is associated with malignant phenotype and poor prognosis. 20, 21 Less is known about the expression of EGFR in CSCC. Several small studies have shown that 43% to 80% of CSCCs express membranous EGFR, but this increases to 100% for metastatic CSCC. In primary tumors, one group demonstrated baseline activation of EGFR in 5 of 9 specimens with detectable EGFR expression. While cetuximab has been wellstudied for the treatment of mucosal SCCs, the benefit for CSCC is not well understood. [22] [23] [24] [25] Barnes et al 21 have shown in vitro efficacy of an EGFR inhibitor, Iressa on CSCC, and several case reports have examined the efficacy of various EGFR inhibitors and have suggested the benefit of combination therapy with a second agent.
EGFR and IGF-IR are logical targets for molecular therapy of cancer based on their frequent overexpression and established roles in the pathogenesis and progression of numerous cancers. 18, 19, 26 Recently, dual inhibition of receptor tyrosine kinases has emerged as a method to improve the efficacy of targeted therapy. Previous studies of single agents have shown that tumors often have complex regulation involving multiple protein tyrosine kinases and may use these pathways as escape mechanisms when a single receptor is targeted. 25, 27 In this study, we analyzed the effects of targeted therapy against IGF-IR and EGF-R on CSCC cell lines. We hypothesize that targeted therapy against IGF-IR (A12) and EGFR (cetuximab) will inhibit CSCC tumor growth in vitro and in an athymic nude mouse model.
MATERIALS AND METHODS
Cell Lines and Culture Conditions. The CSCC cell lines Colo16, SRB1, and SRB12 were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), sodium pyruvate, L-glutamine, vitamins, non-essential amino acids (all from Life Technologies, Rockville, MD), and penicillin-streptomycin (Flow Laboratories, Rockville, MD). Adherent monolayer cultures were maintained on plastic and incubated at 37 C in an atmosphere of 5% carbon dioxide and 95% air. The cultures were maintained no longer than 12 weeks after recovery from frozen stocks. These 3 cell lines were genotyped using short tandem repeat analysis and have been found to be unique and distinct from other cell lines in the American Type Culture Collection and our laboratory. Reagents. Cetuximab (ImClone Systems, Branchburg, NJ) was diluted in phosphate-buffered saline (PBS) to the appropriate concentrations for in vitro studies and at a concentration of 5 mg/mL for intraperitoneal injections in the animal study. A12 was generously provided by ImClone Systems. For in vitro administration, A12 was dissolved in PBS to a concentration of 10 mg/mL and further diluted to appropriate final concentration in RPMI 1640 medium with or without 2% FBS, as described below. For in vivo testing, A12 was dissolved in PBS to a concentration of 4 mg/mL. Both cetuximab and A12 solutions were prepared immediately before administration to the mice.
The following antibodies were used: anti-IGF-IRb (C-20) and anti-EGFR (Santa Cruz Biotechnology, Western Blotting. To measure EGFR and IGF-IR expression and phosphorylation in CSCC lines, total cell protein extracts were obtained from Colo16, SRB1, and SRB12 cells. The cells were grown to subconfluence in DMEM supplemented with 10% FBS, washed with PBS, and scraped with lysis buffer, as previously described. 28 The proteins (50 lg) were resolved by polyacrylamide gel electrophoresis and electrophoretically transferred onto nitrocellulose membranes. The membranes were blocked with 1% bovine serum albumin (Sigma-Aldrich) in 0.1% Tween 20 (v/v) in Tris-buffered saline solution for 30 minutes, then probed overnight with the desired primary antibodies. After incubation with the secondary antibody, signals were visualized using enhanced chemiluminescence (Pierce, Rockford, IL).
We performed Western blotting to demonstrate that cetuximab and A12 are able to specifically inhibit the phosphorylation EGFR and IGF-IR in vitro, Western immunoblotting was performed. Cells from all 3 lines were incubated in serum-free medium for 24 hours. Then, the cells were incubated with either A12 (50 nM), cetuximab (1 lg/mL) or a combination of A12 and cetuximab for 2 hours. Untreated cells were used as a control. The cells were then stimulated with both IGF-I (10 nM; R&D Systems, Minneapolis, MN) and EGF (10 nM; Upstate Biotechnology, Lake Placid, NY) for 15 minutes. Cells were then processed and Western blotting analysis was performed, as described above.
Colo16 cells were further used to test the ability of cetuximab and A12 to inhibit the EGFR and IGF-IR signaling pathways. After serum starvation overnight, the cells were incubated with no cetuximab, A12, or the combination; untreated cells were used as control. The cells were stimulated with both IGF-I and EGF for 15 minutes. Cells were then processed and Western blot analysis was performed, as described above.
Measurement of Cell Proliferation. We used a 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay to test the ability of cetuximab and A12 to inhibit the proliferation of all 3 CSCC lines in vitro. Two thousand cells per well were grown in DMEM medium supplemented with 10% FBS in 96-well tissue culture plates. After 24 hours, the cells were treated with various concentrations of A12 (0.1-100 nM) or cetuximab (0.01-50 ug/mL) diluted in DMEM medium supplemented with 2% FBS. To measure the number of metabolically active cells after a 3-day incubation period, we used an MTT and quantified the results at an optical density of 570 nm using a 96-well microtiter plate reader (MR-5000; Dynatech Laboratories, Chantilly, VA).
Measurement of Cell Death. Colo16 cells were plated at a density of 2 Â 10 5 cells per well in 38-mm 2 6-well plates (Costar, Cambridge, MA) and maintained for 24 hours. Then, A12 was added in various concentrations (0-100 nM) with or without cetuximab (5 lg/ mL) in DMEM medium supplemented with 2% FBS. After 48 hours, the extent of cell death was determined by propidium iodide (PI) staining of hypodiploid DNA. For PI staining, the treated cells were resuspended in a Nicoletti buffer (50 lg/mL PI [Sigma-Aldrich], 0.1% sodium citrate, and 0.1% Triton X-100) for 20 minutes at 4 C. Cell cycle data were then analyzed by flow cytometry, and the sub-G0/G1 fraction was measured using the Multicycle System (Phoenix Flow System, San Diego, CA).
Effects of A12 and Cetuximab on the Growth of Cutaneous Squamous Cell Carcinoma Xenografts in
Nude Mice. CSCC xenografts in nude mice were established as described previously. 28, 29 Briefly, 1 Â 10 6 cells in an injection volume of 100 lL were injected subcutaneously into the right side of the face of each mouse using a 30-gauge needle. The tumors were allowed to develop for 7 days. The mice were then randomized into 4 groups (10 mice per group), and the drugs were administered as follows: (1) A12, 40 mg/kg twice per week by IP injection; (2) cetuximab, 50 mg/kg twice per week IP; (3) both A12, 40 mg/kg, and cetuximab, 50 mg/kg, IP, twice per week; and (4) 250 lL of PBS administered IP twice per week as placebo.
The mice were treated for 18 days and weighed twice per week. Animals would have been humanely killed if they lost >20% of their body weight or if they became moribund. However, all the animals maintained their weight and none had to be humanely killed due to the above criteria before the end of the treatment period. At the end of the 18-day treatment period, the mice were humanely killed by CO 2 asphyxiation and necropsy was performed. The cervical lymph nodes, the lungs, and the skin tumors were removed, sectioned, stained with hematoxylin-eosin, and examined for the presence of metastasis. During necropsy, the tumor size was measured in 2 dimensions and the volume was determined using the formula V ¼ (length; width 2 ) p/6, expressed in cubic millimeters. Drug treatment continued until the day of death with the last dose administered 2 hours before the animal was humanely killed. Tumor inhibition was calculated as a percentage according to the formula (1-[T/C]) Â 100 in which T and C represent the mean tumor volumes of the treatment group and the control group, respectively.
For immunohistochemical and routine hematoxylin-eosin staining, half of the tumor was fixed in formalin and embedded in paraffin. The remainder was embedded in OCT compound (Miles, Elkhart, IN), rapidly frozen in liquid nitrogen, and stored at minus 80 C.
Effects of A12 and Cetuximab on the Survival of Nude Mice Bearing Cutaneous Squamous Cell
Carcinoma Xenografts. CSCC xenografts were established in nude mice as described above. Seven days after the tumor cell injection, the mice were randomized into 4 groups (5 mice per group): control, A12, cetuximab, and a combination group. Each group of mice was treated with PBS, A12, cetuximab, or both agents, as described in the previous section. The mice were weighed twice per week and humanely killed if the animals showed weight loss of >20% or seemed moribund. The mice were treated for 5 weeks.
Immunohistochemistry on Murine Tumor Tissue
Sections. For IGF-IRb, EGFR, and PCNA staining, paraffin-embedded sections were first deparaffinized in xylene. Excess xylene was removed by washing the slides in ethanol. The tissue was treated with pepsin for 20 minutes at 37 C. Immunohistochemistry was performed as previously described. 30 For staining with antibodies against pIGF-IRb, pEGFR, and CD31/PECAM-1, frozen tumors were sectioned (8 to 10 m thick), mounted on positively charged Superfrost slides (Fisher Scientific, Pittsburgh, PA), air dried for 30 minutes, and fixed in cold acetone for 10 minutes. Immunohistochemistry was performed, as previously described. 30 For TUNEL staining, tissues were fixed with 4% paraformaldehyde (methanol free) for 10 minutes at room temperature, washed twice with PBS for 5 minutes, and then incubated with 0.2% Triton X-100 for 15 minutes at room temperature. Then the tissue sections were incubated with reaction buffer containing 44 lL of equilibration buffer, 5 lL of nucleotide mix, and 1 lL of terminal deoxynucleotidyl transferase (Promega kit) at 37 C for 1 hour, avoiding exposure to light. The reaction was terminated by immersing the samples in 2Â saline-sodium citrate buffer for 15 minutes. The samples were then washed 3 times for 5 minutes with PBS to remove unincorporated fluorescein-dUTP.
Immunofluorescence microscopy was performed using a Zeiss Axioplan2 microscope (Carl Zeiss, Thornwood, NY) equipped with a 100-W HBO mercury bulb and filter sets (Chroma, Brattleboro, VT) to individually capture red and blue fluorescent images. Images were captured using a C5810 Hamamatsu color chilled 3-chip charge-coupled device camera (Hamamatsu, Hamamatsu City, Japan) and digitized using Optimas imaging software (Silver Spring, MD). The stained sections were imaged with a Microphot-FX microscope (Nikon, Melville, NY) equipped with a 3-chip chargedcouple device color video camera (Model DXC990; Sony Corp, Tokyo, Japan).
For evaluation of PCNA and CD31 staining, the mean positive area was quantified in 5 random 0.159 mm 2 fields (magnification, Â100) per slide from 5 slides per study group using Image-Pro Plus software package (Media Cybernetics, Silver Spring, MD). For TUNEL staining quantification, the labeled cells were counted in 5 random 0.159 mm 2 fields (magnification, Â100) per slide from a total of 5 slides per study group. The photomontages were prepared using Photoshop software (Adobe Systems, San Jose, CA).
Statistical Analysis. The nonparametric Wilcoxon rank-sum test was used to assess differences in mouse tumor volume between each treatment group and the control group. We ran a repeated-measures regression model with treatment, time, and treatment by time interaction to compare the tumor volumes observed for the group receiving A12 plus cetuximab with the group receiving cetuximab alone. This methodology was also used to compare tumor volumes from the group receiving A12 plus cetuximab to the group receiving A12 alone. Survival was analyzed with the Kaplan-Meier method. Differences between treatment and control groups were compared to the log-rank test. We compared the results from PCNA, CD31, and TUNEL staining by independent-samples t test. Least-squares fit curves were generated for the MTT and PI assays. SPSS 12.0 for Windows software (SPSS, Chicago, IL) was used for all statistical analysis. A p value of .05 was considered significant.
RESULTS

Epidermal Growth Factor Receptor and Insulin-Like
Growth Factor-I Receptor are Expressed by Cutaneous Squamous Cell Carcinoma Cell Lines. Western blot analysis revealed that both cell lines tested stained positively for EGFR and IGF-IR (Figure 1) . Only the Colo16 cell line exhibited baseline phosphorylation of both EGFR and IGFR; the SRB12 cell line showed a weak positive for pIGF-IR.
A12 and Cetuximab Treatment Leads to Decreased Phosphorylation of Their Target Receptors in
Cutaneous Squamous Cell Carcinoma Cell Lines. We evaluated the ability of A12 and cetuximab to inhibit the phosphorylation of EGFR and IGF-IR in the Colo16 and SRB1 cell lines (Figure 1 ). Under basal conditions in serum-free medium, there was a low level of EGFR autophosphorylation, which was enhanced after exposure to EGF (Figure 1 ). Baseline expression of pIGF-1R was minimal; however, phosphorylation occurred upon stimulation with IGF-1. In contrast, there were low levels of pIGF-1R but not pEGFR at baseline in SRB1 cells; both receptors were similarly activated with growth factor stimulation ( Figure 1B) . Treatment with A12 blocked phosphorylation of IGF-IR and resulted in decreased expression of IGF-1R in both cell lines, but this effect was more pronounced for Colo16. EGFR phosphorylation was blocked with cetuximab treatment but not impacted by A12 treatment in both cell lines. No differences in total EGFR expression levels were noted in either cell line.
Treatment with A12 and Cetuximab Decreases Proliferation of Certain Cutaneous Squamous Cell
Carcinoma Cell Lines. We examined the effect of A12 treatment on the proliferation of 2 CSCC cell lines (Colo16 and SRB1) using the MTT assay. The growth of cells incubated with increasing concentrations (0-100 nM) of A12 in DMEM containing 2% serum was determined 72 hours after the addition of the drug ( Figure  2A ). Treatment with various concentrations of A12 did not significantly inhibit proliferation in any of the cell lines studied, although a trend toward inhibition of the Colo16 cells was noted. Next, we performed MTT assays using the Colo16 cell line to compare the effect of treatment with cetuximab with the A12/cetuximab combination on cell proliferation. Proliferation of Colo16 cells was inhibited by treatment with cetuximab alone, and to a greater extent by the combination of A12 and cetuximab in a dose-dependent manner (p < .01; Figure 2B ).
Treatment with A12 and Cetuximab Leads to
Induction of Apoptosis in the Colo16 Cell Line. We examined the effect of dual inhibition of EGFR and IGF-IR on the rate of apoptosis of the Colo16 cell line using PI and flow cytometry. Treatment with A12 alone at increasing concentration did not significantly alter the baseline rate of apoptosis, whereas combination treatment with cetuximab leads to induction apoptosis (11.9% vs 22.7%; p < .012; Figure 3) . Carcinoma. The Colo16 cell lines was used for all in vivo experiments based on the strength of inhibition of intracellular signaling by A12 and cetuximab that was noted previously (Figure 1 ). Cells were injected into the mice as described with visually evident tumors noted at 1 week after inoculation. Treatment with either A12 or cetuximab alone reduced the growth of Colo16-derived SCC xenografts in nude mice by 51% (p ¼ .058) and 49% (p ¼ .041), respectively, when compared to the control group ( Figure 4A ). Mice treated with A12 in addition to cetuximab showed a 92% decrease in the mean estimated tumor volume when compared to the control group (p < .001) or animals treated with either cetuximab or A12 alone (p < .05).
Treatment with A12 Alone and in Combination with Cetuximab Improves Survival in an Orthotopic
Nude Mouse Model of Cutaneous Squamous Cell Carcinoma. A12 and cetuximab were both well tolerated by the animals without substantial adverse effects. None of the animals had to be humanely killed due to weight loss or systemic malignancy, but rather were killed when the local tumor burden became excessive (defined as >1 cm in the maximum dimension or significant ulceration). Treatment with A12 or cetuximab alone resulted in significantly greater survival as compared to the control group (p ¼ .044 and p ¼ .023, respectively; Figure 4B ). The combination treatment group also demonstrated a significantly improved survival rate as compared to the control group (p < .001) or A12-only group (p < .01). There was no statistically significant difference in survival between the combination treatment group and the group treated with cetuximab alone (p > .1).
Treatment of Cutaneous Squamous Cell Carcinoma
Cell Lines with A12, Cetuximab, and A12/Cetuximab Combination in an Orthotopic Tumor Model Leads to Induction of Apoptosis, Decreased Cell Proliferation, and Inhibition of Angiogenesis. The effect of A12 and cetuximab on cellular proliferation was determined by assessing the expression of PCNA in tumor sections harvested at necropsy from mice in all treatment groups. Mean positive area analysis of PCNA staining showed a significant decrease in cell proliferation in mice treated with either cetuximab (p ¼ .016) or A12 alone (p ¼ .026) as compared to the control group (Figures 5A and 5B) . Moreover, there was an additional decrease in cell proliferation in mice treated with A12/cetuximab combination as compared to the control group (p < .001). However, the effects of combination treatment on cell proliferation were not significantly different from treatment with either A12 or cetuximab alone (p > .1).
To assess the degree of intratumoral apoptosis, the tumor sections were stained for DNA fragmentation using the TUNEL method ( Figures 5A and 5C ). The mean number of apoptotic cells per unit area (AE SD) in the tumors of control mice and the mice treated with cetuximab were 11.8 AE 7.4 and 18.2 AE 9.0, respectively (p ¼ .102). Treatment with either A12 alone or A12 in combination with cetuximab increased the mean number of apoptotic cells per unit area to 39.7 AE 20.3 and 35.3 AE 13.6, respectively, representing a significant increase in intratumoral apoptosis when compared to the control group (p ¼ .001 and p ¼ .001) or the cetuximab-only group (p ¼ .007 and p ¼ .016).
To determine the intratumoral microvessel density, we stained tumor sections with CD31-specific antibodies. Treatment with either A12 or cetuximab alone resulted in a statistically significant inhibition of tumor-associated angiogenesis as defined by the mean CD31-positive area when compared to the control group (p < .001 and p < .001, respectively; Figures 5A and 5D ). Treatment with A12 in combination with cetuximab resulted in an additional inhibition of tumor-associated angiogenesis when compared to the control group (p < .001) or the group treated with cetuximab only (p ¼ .003).
DISCUSSION
Our findings indicate that the combination of A12 and cetuximab simultaneously blocks EGFR and IGF-IR activation and significantly reduces tumor volume by both direct antitumor and angiogenic effects. We showed that elevated IGF-IR and EGFR expression is consistently and concurrently elevated in CSCC cell lines. In an orthotopic nude mouse model of CSCC, dual inhibition with A12 and cetuximab reduced the tumor volume by 92% as compared to approximately 50% with either agent alone. Combination treatment also significantly improved survival. In vitro studies demonstrated the inhibition of activation of IGF-IR by A12 and EGFR by cetuximab, but showed no cross-inhibition. The combination of A12 and cetuximab also showed direct growth inhibitory and apoptotic activity against CSCC cell lines. In vivo monotherapy with either A12 or cetuximab caused a significant increase in apoptosis and a decrease in both cellular proliferation and microvessel density as compared to the control group, an effect which was enhanced for combination treatment.
A12 treatment resulted in downregulation of the total IGF-IR expression levels, as has been demonstrated by others. 18 These results are also consistent with previous studies of EGFR and IGF-IR overexpression in CSCC specimens and cell lines. 5, 31 We also showed that A12 has effects on downstream kinases, such as AKT, confirming similar findings by Wang et al. 32 Both A12 and cetuximab when used as single agents demonstrated only minor antiproliferative activity on CSCC cell lines, whereas combination treatment led to a significant inhibition of growth (p < .01). This finding is consistent with multiple studies demonstrating the efficacy of dual inhibition of EGFR and IGF-IR pathways in inhibiting tumor cell proliferation as compared to targeting a single pathway. 31 In contrast to studies of small molecule IGF-IR kinase inhibitors, treatment with A12 alone did not significantly increase apoptosis of CSCC in vitro. These data suggest that A12 exerts its antiproliferative effect mainly through a cytostatic, rather than cytotoxic, mechanism. Similar results have been reported in other studies using single agent inhibitors including IGF-IR antibodies (EM164, h7C10, and CP-751,871) and inhibitors of EGFR including AG 1478, mAb225, and gefitinib. 15, 28, 29, 33, 34 Treatment with A12 and cetuximab significantly inhibited SCC tumor growth in the murine model. Either agent alone resulted in approximately a 50% reduction in tumor volume, whereas treatment with a combination of the 2 drugs resulted in a greater than 90% reduction in tumor volume. Similarly, longer survival was also found for the combined treatment group as compared with the control or A12 treatment groups. Differences in sensitivity to inhibition of either EGFR or IGF-IR alone have previously been found in other tumors. 35 However, the concurrent expression of both IGF-IR and EGFR together in CSCC seems to be important for tumor growth and development, and simultaneous inhibition of these 2 tyrosine kinases results in a significantly greater reduction of tumor development and growth. Our findings are consistent with other studies suggesting that targeted therapy of IGF-IR can be used in combination with other therapeutic strategies to achieve maximum antitumor effects 26, 27, 36 and that combination therapy may be beneficial in preventing the development of drug resistance, such as that seen with trastuzumab (Herceptin), erlotinib, and gefitinib. 27, 37, 38 Immunohistochemical analyses of tumor sections from mice treated with either A12 or cetuximab alone revealed a significant decrease in the proliferative index as measured by PCNA staining and an increase in intratumoral apoptosis as measured by the TUNEL assay. This effect was strongest for groups treated with A12, either alone or in combination, which is in agreement with previous work showing only moderate apoptosis in response to cetuximab treatment alone but synergism with dual agent therapy. The increase in intratumoral apoptosis and decrease in proliferation is in contrast to our in vitro findings showing limited effects of either agent or the combination on the growth of Colo16 cells. The differences between the results from the animal model and in vitro experiments can be explained by reports showing the activation of vascular endothelial growth factor receptor (VEGFR) signaling by IGFR in cancer. 39 Recent studies have demonstrated that both EGFR and IGF-IR are abundantly expressed on endothelial cells. 5, [40] [41] [42] [43] EGF and IGF produced at high levels by tumors are able to promote the growth, survival, and migration of tumor cells, and induce the synthesis of VEGF-A, VEGF-C, and MMP2, which may enhance the development of the blood supply essential for the progressive growth of primary malignancies and their metastases. 21, [44] [45] [46] Treatment with either A12 or cetuximab alone resulted in statistically significant inhibition of tumor-associated angiogenesis, whereas the combination treatment with A12 and cetuximab resulted in an additional inhibition of angiogenesis ( Figures 5A, and 5C ). These findings concur with other studies that have demonstrated reduction of angiogenesis resulting from inhibition of IGF-IR, EGFR, or both receptors simultaneously. 5, 45 Current studies have indicated that the efficacy of tyrosine kinase inhibition can be enhanced by combining it with other tyrosine kinase inhibitors, chemotherapy, or radiotherapy. 45, [47] [48] [49] [50] Although a demonstrable response was achieved using A12 or cetuximab as single agents, the enhanced response obtained when these 2 monoclonal antibodies were used in combination provides further support for the use of not only multiple tyrosine kinase inhibitors, but the use of inhibitors of IGF-IR and EGFR in particular. [51] [52] [53] [54] This agrees with previous works showing a synergistic effect of the combination of IGF-IR and EGFR inhibition and suggests the presence of ''crosstalk'' between the receptors. 33 In summary, dual inhibition of the tyrosine kinases EGFR and IGF-IR can decrease skin cancer growth both in vitro and in vivo. Administration of the IGF-IR antibody A12 can significantly inhibit the proliferation of SCC cells in vitro. Treatment with A12 alone or in combination with cetuximab significantly reduces tumor volume and prolongs the survival time of nude mice implanted with CSCC by enhancing their respective cytostatic effects and inducing antiangiogenesis. These data suggest that dual inhibition of tyrosine kinases, EGFR and IGF-IR in particular, may be therapeutically useful and provide a promising strategy for the treatment of patients with aggressive CSCC.
